Bimagrumab (BYM338) is a fully human monoclonal antibody that binds and blocks the activin receptor type II (ActRII), preventing signaling from myostatin, activin A, and other ActRII ligands that negatively regulate skeletal muscle mass. By blocking…
In the full monograph
- What it is, and how it works
- What the evidence shows — randomized trials, observational data, animal studies, graded and cited
- Dose, form, and timing
- What to expect, and how soon
- Who should be careful, and what to check first
- The verdict
MEMBERS
Read the full monograph
Members get every monograph in the library, the research assistant, and the stack tracker — with a 30-day money-back guarantee. Not ready? Start free with the Proven Supplements Starter Guide.